Lecamenab is an investigational monoclonal antibody targeting amyloid-beta plaques in the brain, designed to slow cognitive decline in early Alzheimer’s disease. Administered via intravenous infusion, it aims to clear toxic protein buildup. Patients with mild symptoms and confirmed amyloid pathology may benefit most, offering hope for preserving memory and function longer.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends